18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies

PET Clin. 2022 Jul;17(3):369-388. doi: 10.1016/j.cpet.2022.03.007.

Abstract

Molecular imaging with PET-computerized tomography (PET-CT) plays an important role in oncology. There is current and evolving evidence supporting the use of fluorodeoxyglucose (FDG) and non-FDG tracers in assessment patients with hepatobiliary and pancreatic cancers in various clinical scenarios. In this chapter, we discuss the advantages and limitations of FDG and non-FDG PET-CT in the management of patients with hepatobiliary and pancreatic cancers.

Keywords: Cholangiocarcinoma; Gall bladder cancer; Hepatocellular cancer; Pancreatic cancer.

Publication types

  • Review

MeSH terms

  • Fluorodeoxyglucose F18*
  • Humans
  • Neoplasm Staging
  • Pancreatic Neoplasms* / diagnostic imaging
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18